Kamada Ltd. (KMDA): Price and Financial Metrics


Kamada Ltd. (KMDA): $4.65

0.03 (+0.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

KMDA POWR Grades

  • Growth is the dimension where KMDA ranks best; there it ranks ahead of 96.94% of US stocks.
  • KMDA's strongest trending metric is Momentum; it's been moving down over the last 84 days.
  • KMDA's current lowest rank is in the Momentum metric (where it is better than 7.21% of US stocks).

KMDA Stock Summary

  • KMDA has a higher market value than 28.09% of US stocks; more precisely, its current market capitalization is $195,919,524.
  • Over the past twelve months, KMDA has reported earnings growth of 121.22%, putting it ahead of 88.4% of US stocks in our set.
  • The volatility of KAMADA LTD's share price is greater than that of just 15.74% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to KMDA, based on their financial statements, market capitalization, and price volatility, are NURO, SCYX, WPRT, CRNT, and IMRN.
  • Visit KMDA's SEC page to see the company's official filings. To visit the company's web site, go to www.kamada.com.

KMDA Valuation Summary

  • In comparison to the median Healthcare stock, KMDA's price/sales ratio is 68.09% lower, now standing at 1.5.
  • Over the past 119 months, KMDA's price/sales ratio has gone down 3.3.

Below are key valuation metrics over time for KMDA.

Stock Date P/S P/B P/E EV/EBIT
KMDA 2023-03-24 1.5 1.1 -84.4 -157.5
KMDA 2023-03-23 1.5 1.1 -84.2 -157.2
KMDA 2023-03-22 1.5 1.1 -83.8 -156.6
KMDA 2023-03-21 1.5 1.1 -84.4 -157.5
KMDA 2023-03-20 1.5 1.1 -82.0 -153.4
KMDA 2023-03-17 1.5 1.1 -81.7 -152.9

KMDA Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -129.92%.
  • Its 4 year revenue growth rate is now at 79.81%.
  • Its 3 year revenue growth rate is now at -13.72%.
Over the past 18 months, KMDA's revenue has gone down $9,487,000.

The table below shows KMDA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 115.369 16.875 -10.274
2022-06-30 106.186 8.711 -11.603
2022-03-31 106.835 -5.456 -6.745
2021-12-31 103.642 -8.819 -2.23
2021-09-30 103.715 8.899 4.408
2021-06-30 116.006 9.189 12.088

KMDA Price Target

For more insight on analysts targets of KMDA, see our KMDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.00 Average Broker Recommendation 1.5 (Moderate Buy)

KMDA Stock Price Chart Interactive Chart >

Price chart for KMDA

KMDA Price/Volume Stats

Current price $4.65 52-week high $5.85
Prev. close $4.62 52-week low $3.72
Day low $4.55 Volume 10,600
Day high $4.66 Avg. volume 33,244
50-day MA $4.43 Dividend yield N/A
200-day MA $4.59 Market Cap 208.41M

Kamada Ltd. (KMDA) Company Bio


Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company was founded in 1990 and is based in Ness Ziona, Israel.


KMDA Latest News Stream


Event/Time News Detail
Loading, please wait...

KMDA Latest Social Stream


Loading social stream, please wait...

View Full KMDA Social Stream

Latest KMDA News From Around the Web

Below are the latest news stories about KAMADA LTD that investors may wish to consider to help them evaluate KMDA as an investment opportunity.

KMDA: 2022 Revenue of $129 Million; Expected 2023 Revenues of $138 Million to $146 Million and Continued Positive Operating Cash Flow…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On March 15, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the fourth quarter and full year 2022 and provided a business update. Kamada reported revenues of $129.3 million, which met the company’s previously announced guidance, and was a 25% increase compared to fiscal year 2021. The increase was

Yahoo | March 20, 2023

Kamada Ltd. (NASDAQ:KMDA) Q4 2022 Earnings Call Transcript

Kamada Ltd. (NASDAQ:KMDA) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Greetings. Welcome to the Kamada Ltd. Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please note, this conference is being recorded. At this time, […]

Yahoo | March 18, 2023

Kamada Issues 2023 CEO Letter to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear Shareholders, Colleagues and Business Partners: The recently completed 2022 year was a transformational period for Ka

Yahoo | March 15, 2023

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase Year-over-YearFiscal Year 2022 EBITDA of $17.8 million, Represented Margins of 14%, and a 3x Increase Over Fiscal Year 2021Recorded Highest Annual Operating Cash Flow in Kamada's History of $28.6 Million in Fiscal Year 2022; $34.3 Million Cash Position as of December 31, 2022, Nearly Double Cash Position at Year-End

Yahoo | March 15, 2023

Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023

REHOVOT, Israel and HOBOKEN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2022, prior to the open of the U.S. financial markets on Wednesday, March 15, 2023. Kamada managemen

Yahoo | March 9, 2023

Read More 'KMDA' Stories Here

KMDA Price Returns

1-mo 5.68%
3-mo 15.96%
6-mo 3.10%
1-year -15.76%
3-year -20.24%
5-year 1.09%
YTD 15.96%
2022 -39.06%
2021 1.54%
2020 -5.12%
2019 36.60%
2018 5.26%

Continue Researching KMDA

Want to see what other sources are saying about Kamada Ltd's financials and stock price? Try the links below:

Kamada Ltd (KMDA) Stock Price | Nasdaq
Kamada Ltd (KMDA) Stock Quote, History and News - Yahoo Finance
Kamada Ltd (KMDA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8556 seconds.